After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

Amid consumer angst and political pressure over the cost of life-saving insulin, Sanofi announced Thursday it would slash the price of its most-prescribed insulin, Lantus. Sanofi said it will cut the ...

Biosimilars have been quietly moderating drug prices in the background, Bernstein analyst Ronny Gal said in a recent report. Now, armed with their first biosimilar green light of 2021, Biocon and ...